During the corresponding time, Evoke Pharma Inc recorded a revenue increase by 61.4 % year on year, sequentially revenue grew by 14.17 %. While revenue at the Evoke Pharma Inc 's corporate clients
Evoke Pharma Inc's Comment on Sales, Marketing and Customers
The company focuses on the gastroparesis treatment market with its product Gimoti, which competes against metoclopramide oral formulations, erythromycin, and domperidone. Metoclopramide is currently the only FDA-approved treatment for gastroparesis in the U.S., available as generic versions and branded as Reglan® Tablets by Ani Pharmaceuticals. In 2009, Salix Pharmaceuticals, Inc. introduced an orally dissolving metoclopramide tablet. Other companies developing treatments for gastroparesis include Vanda Pharmaceuticals Inc. (tradipitant), CinRx (deudomperidone/CIN-102), Processa Pharmaceuticals (PCS12852), and Renexxion (Naronapride), with products in various clinical trial stages targeting gastroparesis patients, including those with diabetic gastroparesis. The company is also developing an intellectual property portfolio for Gimoti in the U.S. and internationally.
Evoke Pharma Inc’s Comment on Sales, Marketing and Customers
The company focuses on the gastroparesis treatment market with its product Gimoti, which competes against metoclopramide oral formulations, erythromycin, and domperidone. Metoclopramide is currently the only FDA-approved treatment for gastroparesis in the U.S., available as generic versions and branded as Reglan® Tablets by Ani Pharmaceuticals. In 2009, Salix Pharmaceuticals, Inc. introduced an orally dissolving metoclopramide tablet. Other companies developing treatments for gastroparesis include Vanda Pharmaceuticals Inc. (tradipitant), CinRx (deudomperidone/CIN-102), Processa Pharmaceuticals (PCS12852), and Renexxion (Naronapride), with products in various clinical trial stages targeting gastroparesis patients, including those with diabetic gastroparesis. The company is also developing an intellectual property portfolio for Gimoti in the U.S. and internationally.
Sources:
Evoke Pharma Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Evoke Pharma Inc’s corporate clients.
For your research, we’ve provided 9 tables on Evoke Pharma Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
100 %